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Background: To report the rate of cystoid macular oedema (CMO) as detected by spectral-domain optical coherence
tomography (SD-OCT) after intraoperative complication during phacoemulsification. The secondary objectives include
comparing mean macular thickness and best-corrected visual acuity (BCVA) between those who developed postoperative
CMO against those who did not.
Methods: This is a prospective cohort study conducted in a tertiary hospital between July 2009 and June 2010. Serial
SD-OCT and BCVA were performed at baseline, 1 week, 6 weeks and 16 weeks postoperatively.
Results: Single eyes from 47 subjects were analyzed; of these 16 (34%) eyes developed CMO. In the CMO group, mean
macular thickness (±SD) increased sharply by 56 μm from 273 ± 24 μm at baseline to 329 ± 31 μm at 16 weeks; whereas
in the non-CMO group, macular thickness showed a slight increase of 14 μm from 259 ± 21 μm to 272 ± 20 μm. In
the CMO group, mean BCVA (in logarithm of minimum angle of resolution) improved modestly from 0.92 ± 0.66 to
0.66 ± 0.41 at week 16; while in the non-CMO group, mean BCVA improved markedly from 0.98 ± 0.59 to 0.21 ± 0.13.
The two groups differed significantly in mean macular thickness (p < 0.001) and mean BCVA (p < 0.001) at 16 weeks.
Conclusion: As detection rate of CMO is high, postoperative OCT monitoring for patients with intraoperative
complications allows earlier diagnosis and treatment.
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Intraoperative complicationBackground
Postoperative cystoid macular oedema (CMO) is an import-
ant cause of disappointing vision after phacoemulsification,
especially if intraoperative complication occurs. The inci-
dence of CMO varies widely across literature. This in part
is due to the various ways of defining and diagnosing
CMO as well as the type of cataract surgery performed
[1]. Clinical and clinically-significant CMO are terms used
for patients with angiographic evidence of CMO accom-
panied by a decrease in best-corrected visual acuity
(BCVA) [2]. For cataract surgery, this is usually taken as* Correspondence: gideon_khaw@hotmail.com
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reproduction in any medium, provided the orbeing worse than logMAR of 0.3 (or Snellen visual acuity
of 20/40) [3].
Traditionally, fluorescein angiography (FA) is used to
confirm the presence of perifoveal leakage. In severe
cases, this is classically seen as a petaloid pattern of
hyperfluorescence in the late frames. Currently, optical
coherence tomography (OCT) is a non-invasive method
that can give high-resolution, cross-sectional images of
the retina and its thickness. Spectral-domain OCT
(SD-OCT) provides an axial resolution of 5 μm, thus
allowing better visualization of the retinal layers to
specifically detect subtle intraretinal changes [4]. It is
superior to FA in the diagnosis of CMO in that it is easy
to perform, safe, objective and quantifiable. Furthermore,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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than FA in detecting CMO associated with retinal vein
occlusion, age-related macular degeneration and diabetic
retinopathy. They found that CMO was missed by FA in
18.5%, 33.33% and 33.33% of these cases respectively [5].
Using OCT, transient and clinically insignificant changes
in the macular thickness have been observed after unevent-
ful phacoemulsification [6,7]. In a series by Ching et al.,
only 3% of cases (4/131) demonstrated tomographically-
evident-CMO by 8 weeks after uncomplicated phacoemul-
sification [8]. Following vitreous loss, the incidence of
clinical CMO is higher, between 6-21% [9]. However, these
studies lack uniformity in terms of the type of cataract sur-
gery performed (phacoemulsification, extracapsular cataract
surgery or intracapsular cataract surgery) as well as how
CMO was diagnosed (clinical, angiographic or OCT).
We are unable to find any prospective study that utilizes
OCT to detect the rate of CMO after intraoperative
complication during phacoemulsification. Hence our study
aims to address this issue. Our secondary objectives are
to compare the mean macular thickness and BCVA of
patients who developed postoperative CMO against those
who did not.
Methods
We conducted a prospective cohort study which adhered
to the Declaration of Helsinki. Institutional Review Board
approval was obtained and all subjects gave informed
consent prior to enrollment into the study.
Study participants consisted of consecutive cohort of
patients who underwent phacoemulsification with intraop-
erative complication in the University of Malaya Medical
Center between July 2009 and June 2010. Intraoperative
complication was defined based on similar studies and
included the presence of any of the following conditions,
whether in isolation or in combination: posterior cap-
sule rent, zonulodialysis, presence of vitreous loss, dropped
nucleus, complications needing enlargement of the corneal
wound or a second operation and position of the intraocu-
lar lens other than in-the-bag [10,11].
All patients 21 years of age or older with sufficient
media clarity to permit preoperative OCT evaluation were
eligible for inclusion in the study. Our exclusion criteria
included patients on prostaglandin analogues, topical or
systemic steroid or non streroidal anti-inflammatory
drugs, history of uveitis, prior intraocular injections or
surgery, past or pre-existing retinal and choroidal diseases
that could affect retinal thickness. These included but are
not limited to CMO, diabetic retinopathy or maculopathy,
retinal vein occlusion, age-related macular degeneration,
radiation retinopathy, posterior uveitis and previous laser
treatment. Subjects with abnormal macula based on clin-
ical examination and preoperative macular OCT scans
were excluded from this study.Initial screening was conducted during subjects’ pre-
operative visits two weeks prior to their scheduled pha-
coemulsification. We obtained patient’s detailed history
and performed ophthalmologic examination that included
BCVA, slit-lamp biomicroscopy, intraocular pressure meas-
urement, dilated fundus examination and OCT scans.
Throughout this study, BCVA was performed with re-
fraction. It was measured using a back-illuminated Snellen
chart at 6 meters and converted to logarithm of minimal
angle of resolution (logMAR) scale for analysis. SD-OCT
(Cirrus; Carl Zeiss Meditech, Inc, Jena, Germany) scanning
was done using the macular cube scan (512×128 scan pat-
tern) centered on the fovea. Scans with signal strength 6 or
greater were deemed acceptable. All OCT scans for this
study were performed by two of the authors (KWK and
HHL).
From the preoperative screening, 805 subjects who
met the inclusion and exclusion criteria were identified.
All consented for the study. From these, 48 eyes of 48
patients experienced intraoperative complication during
phacoemulsifiction. They were subsequently reviewed at
1 week, 6 weeks and 16 weeks postoperatively [6-8]. At
each visit, BCVA, slit-lamp examination and OCT scan
were performed. One patient did not complete the sched-
uled follow up. A patient is defined as belonging to the
CMO group if he or she developed CMO at week 16.
After phacoemulsification, all patients received standard-
ized topical steroid and antibiotic drops. This involved
two-hourly topical administration of prednisolone acetate
1% (Pred Forte, Allergan, Irvine, CA) for the first week,
four times daily for one month and then subsequently
tapered. Topical antibiotics were given four times daily
during the same period.
Upon the detection of CMO, a step-wise treatment ap-
proach was employed. In the first instance, correctable
causes like vitreous traction at the wound were addressed.
Subsequently, topical steroid application was intensified
and topical non-steroidal anti-inflammatory drug was
added. No patients with CMO in our series needed more
invasive approaches such as the use of sub-Tenon or in-
travitreal triamcinolone and/or intravitreal anti-vascular
endothelial growth factor.
Data collection included demographic characteristics,
ocular and medical history as well as intraoperative details
such as surgeon’s experience (resident or consultant
ophthalmologist), operation time, type of complication
and intraocular lens position.
The main outcome measure was the rate of postoperative
CMO. This was defined as the presence of hyporeflective
intraretinal cystoid changes noted on SD-OCT which was
not present preoperatively [12]. It was graded by a single
consultant ophthalmologist (VS) who was masked from the
patient’s intraoperative complication, visual acuities and
treatment approach. Secondary outcomes included mean
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who developed postoperative CMO against those who
did not.
Since the patterns of visual improvement dependency
on change in macular thickness for the CMO and non-
CMO group across four time points may be complex,
we explored the data graphically using the scatter plot
and the heat plot. The latter is a powerful graphical
method that is commonly used for exploring patterns in
multidimensional data, such as those from genomic stud-
ies [13]. For statistical analysis, paired t-test was used to
test for significant difference in mean macular thickness
and BCVA between baseline and at 16 weeks for both the
CMO and non-CMO groups. To compare the discrepancy
of mean macular thickness between these two groups at
baseline and at 16 weeks, we used the two-sample t-test
with Bonferonni adjustment (5% significance level). All
graphical plots and statistical analyses were done using R
Version 2.13.2 [14].
Results
During the one-year enrollment period, 805 patients
who met the eligibility criteria were identified. All con-
sented for the study. From these, a total of 48 eyes of 48
patients encountered intraoperative complication during
phacoemulsification. One patient transferred her follow
up to another hospital due to logistical reason. Conse-
quently, 47 eyes of 47 patients completed their 1-week,
6-weeks and 16-weeks follow up. One patient missed
his 6-week follow up visit. The mean age of patients
was 67 ± 8 years (range: 45 to 82 years) and 49% of them
were males.
Of the 48 eyes that underwent phacoemulsification, 25
(47%) were performed on the left eye. Residents oper-
ated on 31 (66%) eyes, while consultant ophthalmolo-
gists operated on 16 eyes. The distribution of operation
time (±SD) for phacoemulsification was bimodal (80 mins
and below: n = 34, 55 ± 14 mins; above 80 mins: n = 13,
123 ± 18 mins). The observed intraoperative complica-
tions are as follows: posterior capsule rent (n = 40),
zonulodialysis (n = 8), vitreous loss (n = 35), enlarge-
ment of corneal wound (n = 35) and dropped nucleus
(n = 7). Vitreous loss accompanied 82% of posterior
capsule rent and 88% of zonulodialysis. With regards to
the size of nucleus drop, three cases were larger than a
quarter nucleus size.
There were seven cases that needed a second surgery.
The reasons for surgery included dropped nucleus (n = 3),
retained cortex (n = 2), wound leak (n = 1) and secondary
lens implantation (n = 1). All were performed within a
week from the first surgery. With regards to intraocular
lens implantation, 9 cases had in-the-bag implantation, 24
in the sulcus and 14 in the anterior chamber. No eyes
were left aphakic. None of the subjects developed post-operative complications such as endophthalmitis or
corneal decompensation.
Acceptable OCT scans were available for all eyes at all
time intervals except 6 eyes at 1-week follow up due to
hazy corneas. In total, 16 eyes (34.0%) developed postop-
erative CMO. Cystoid spaces were detected on SD-OCT
in two eyes at week 1, nine eyes at week 6 and five eyes at
week 16. One eye demonstrated resolution of CMO by
week 16. An example of the serial OCT scans of a subject
who developed postoperative CMO is shown in Figure 1.
At baseline, mean macular thickness in the CMO
group was 273 ± 24 μm; in the non-CMO group, it was
259 ± 21 μm. There was no significant difference in
mean macular thickness between both groups (p = 0.06).
Following complicated phacoemulsification, mean macular
thickness at 16 weeks in the CMO group increased 55 μm,
to 329 ± 31 μm; this increase was biologically significant
(95% CI: [38,73]; p < 0.001). In the non-CMO-group, the
increase was only 14 μm, to 272 ± 20 μm; this increase
was statistically significant (p = 0.01), but relatively un-
important from a biological point of view (95% CI:
[3,24]). Mean macular thickness in the CMO group was
significantly thicker than the non-CMO group by 56 μm
(95% CI: [36, 77]; p < 0.001).
Similarly, baseline BCVA in the CMO group was 0.92 ±
0.66; in the non-CMO group, it was 0.98 ± 0.59. There was
no significant difference in BCVA between both groups
(p = 0.7). Following complicated phacoemulsification, mean
BCVA at 16 weeks in the CMO group decreased to 0.66 ±
0.41. However, this improvement was not statistically sig-
nificant (p = 0.2). In the non-CMO group, mean BCVA
decreased substantially to 0.21 ± 0.13. The magnitude of de-
crease was 0.78, a result that was both statistically and clin-
ically significant (95% CI: [−0.98,-0.21]; p < 0.001). Mean
BCVA in the non-CMO group was significantly less by 0.45
compared to the CMO group (95% CI: [−0.71,-0.19];
p < 0.001) by 16 weeks postoperatively. Furthermore,
about 94% of non-CMO patients ended with BCVA of 0.3
or better, compared to only 38% in the CMO group.
Figures 2 and 3 show the macular thickness and BCVA
profiles of patients in the CMO and non-CMO groups, re-
spectively. The patients are ranked in descending order ac-
cording to macular thickness at week 16. Comparing both
figures, we note that macular thickening is generally more
pronounced in CMO patients compared to non-CMO pa-
tients, as indicated by multiple transitions of colour tones
across the four time periods. Similarly, BCVA improvement
appears to be concentrated in CMO patients who had more
gradual rather than abrupt thickening of the macular.
Discussion
Incidence of CMO after complicated phacoemulsification
This prospective cohort study is, to our knowledge, the
first to report on the incidence of CMO as detected by
Figure 1 Serial macular OCT scans at baseline, postoperative 1 week, 6 weeks and 16 weeks for patient #35 with postoperative CMO.
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intraoperative complications during phacoemulsification.
In our study the rate of tomographic CMO was about
31%. In the literature, the reported percentage of clinical
CMO following intraoperative complication varies widely
from 1.7% to 10% [2,9,15-18]. We note that these studies
were designed primarily to study visual outcome and notspecifically to detect CMO. Also, they are retrospective in
nature, and did not provide details as to how CMO was
diagnosed. Another drawback from studies such as those
by Chan et al. [17] and Blomquist and Rugwani [9] is the
fact that they included various forms of cataract surgery
like extracapsular and intracapsular cataract extractions,
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Figure 2 Heat map of macular thickness and BCVA profiles for CMO patients. Symbols: A for baseline; B for Week 1; C for Week 6; D for
Week 16; NA for missing data due to hazy cornea or appointment default. Each row corresponds to a subject ranked in descending order
according to macular thickness at week 16.
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higher as a consequence of using SD-OCT. Typically,
percentages of angiographic and tomographic CMO are
much higher than clinical CMO. In one study using FA,
the rate of angiographic CMO at 6 weeks after uncom-
plicated cataract surgery was 18.7%, although the rate of
clinical CMO was only 2.1% [3]. More specifically, in the
subgroup with intraoperative complications, the rate of
angiographic CMO and clinical CMO was 11% and 4.8%,
respectively. Previously, Ching et al. used OCT to detect
CMO following uneventful phacoemulsification [8]. They
found 4 out of 131 patients (3%) developed CMO. Unfortu-
nately, these patients were excluded from the analysis and
the serial macular thickness was not given. Minnella et al.
gave OCT details of 15 patients with Irvine-Gass syndrome
[12]. However they did not mention whether these patients
had intraoperative complication during surgery.
Evaluation of serial macular thickness
Besides identifying CMO, OCT enables quantitative
evaluation of macular thickness over time, a feature
not possible with FA. For patients who did not developCMO in our cohort, their serial mean macular thickness
showed a small increase over time (259 μm to 272 μm
in 4 months). This mean change of 14 μm, although
statistically significant, is not clinically significant and
is comparable with other published studies looking at
serial changes of macular thickness following uneventful
phacoemulsification [6-8].
In the CMO group, we found a steady increase in mean
macular thickness over time. It is often quoted that post-
operative CMO only develops 6–8 weeks after surgery
[19]. However in our series we found the onset of CMO
to be gradual rather than occurring at a specific point.
This concurs with newer studies using OCT that detected
a greater percentage of patients with CMO occurring at
an earlier postoperative period. Ching et al. found that
CMO can develop as early as the second postoperative
week [8].
The visualization of patients serial data using the
heat map allows the possibility of correlating patterns
of change in macular thickness with other clinical
symptoms of interest in the future. Such analyses are
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Figure 3 Heat map of macular thickness and BCVA profiles for non-CMO patients. Symbols: A for baseline; B for Week 1; C for Week 6;
D for Week 16; NA for missing data due to hazy cornea or appointment default. Each row corresponds to a subject ranked in descending order
according to macular thickness at week 16.
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In our study, the overall proportion of patients who
achieved BCVA of 0.3 or better was 74% (35/47). In cases
where CMO developed, their BCVA was expectedly
worse. However, in our subgroup that did not develop
CMO, the percentage of good visual outcome is compar-
able to other published data (6% did not achieve BCVA of
0.3 or less). Tan and Karwatowski reported a study from
the United Kingdom that showed that 14% of their 92
patients with complicated phacoemulsification requiring
anterior vitrectomy did not achieve BCVA of 0.3 or less
[18]. Moreover, of those who developed pseudophakic
CMO, all had VA between 0.5 to 0.8. Another study
from Singapore showed that 13% of 115 patients with
posterior capsule rupture failed to achieve BCVA of 0.3
or less [17]. In a large series from Sweden involving 171
patients with capsule complication, 27% did not achieve
BCVA of 0.5 or less [20].Limitations
Our study has several limitations. Firstly, in order to have
larger sample size, we were unable to conduct a single
surgeon study. As such, variability in how complications
were handled and the differences in postoperative
management were to be expected. Secondly, we did not
follow the remaining 753 subjects who consented for the
study but did not encounter any intraoperative complica-
tion during their surgery. Previously our centre reported
serial macular thickness measurements using SD-OCT in
132 patients who underwent uneventful phacoemulsifica-
tion [21]. No CMO cases were detected in this series. As
such we felt that it was a burden to resource and unethical
to subject a large group of cohort to repeated OCT testing.
Conclusion
Nonetheless, we believe the results from this study are
potentially valuable to the surgeon as it highlights the
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patients whounderwent complicated phacoemulsifica-
tion. We recommend routine postoperative OCT mon-
itoring in these patients as the detection rate of CMO
is high and associated with a corresponding decrease in
visual acuity. The prompt diagnosis would allow earlier
treatment to be instituted.
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